What is HC Wainwright’s Estimate for NBIX FY2026 Earnings?

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Investment analysts at HC Wainwright reduced their FY2026 earnings per share (EPS) estimates for Neurocrine Biosciences in a note issued to investors on Thursday, July 31st. HC Wainwright analyst A. Fein now forecasts that the company will earn $4.16 per share for the year, down from their previous forecast of $4.19. HC Wainwright currently has a “Buy” rating and a $168.00 target price on the stock. The consensus estimate for Neurocrine Biosciences’ current full-year earnings is $4.28 per share. HC Wainwright also issued estimates for Neurocrine Biosciences’ FY2027 earnings at $5.90 EPS and FY2028 earnings at $9.64 EPS.

A number of other analysts also recently commented on NBIX. Wall Street Zen raised Neurocrine Biosciences from a “hold” rating to a “strong-buy” rating in a research report on Saturday. BMO Capital Markets increased their price target on Neurocrine Biosciences from $96.00 to $115.00 and gave the company a “market perform” rating in a research report on Tuesday, May 6th. Wedbush raised their target price on Neurocrine Biosciences from $137.00 to $141.00 and gave the stock an “outperform” rating in a research report on Thursday. Piper Sandler raised their target price on Neurocrine Biosciences from $154.00 to $175.00 and gave the stock an “overweight” rating in a research report on Thursday. Finally, Evercore ISI decreased their target price on Neurocrine Biosciences from $190.00 to $185.00 and set an “outperform” rating for the company in a research report on Thursday, April 24th. Three equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $160.90.

Neurocrine Biosciences Trading Up 0.5%

Shares of NBIX opened at $128.91 on Monday. The company has a market capitalization of $12.79 billion, a price-to-earnings ratio of 38.14, a PEG ratio of 1.11 and a beta of 0.25. The stock has a 50 day moving average of $128.26 and a 200 day moving average of $120.74. Neurocrine Biosciences has a 12 month low of $84.23 and a 12 month high of $157.40.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings results on Wednesday, July 30th. The company reported $1.06 EPS for the quarter, beating analysts’ consensus estimates of $0.98 by $0.08. The company had revenue of $687.50 million during the quarter, compared to the consensus estimate of $653.09 million. Neurocrine Biosciences had a return on equity of 13.22% and a net margin of 13.88%. Neurocrine Biosciences’s revenue was up 16.5% on a year-over-year basis. During the same period last year, the business posted $1.63 earnings per share.

Insider Buying and Selling

In other news, insider Ingrid Delaet sold 457 shares of the firm’s stock in a transaction that occurred on Thursday, July 10th. The shares were sold at an average price of $135.00, for a total transaction of $61,695.00. Following the transaction, the insider directly owned 4,730 shares of the company’s stock, valued at approximately $638,550. This trade represents a 8.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Jude Onyia sold 59,819 shares of Neurocrine Biosciences stock in a transaction that occurred on Wednesday, July 9th. The shares were sold at an average price of $130.46, for a total transaction of $7,803,986.74. Following the transaction, the insider directly owned 18,289 shares in the company, valued at approximately $2,385,982.94. The trade was a 76.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 90,251 shares of company stock valued at $11,672,602 in the last ninety days. 4.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On Neurocrine Biosciences

Several institutional investors have recently bought and sold shares of NBIX. Huntington National Bank lifted its stake in shares of Neurocrine Biosciences by 73.5% during the fourth quarter. Huntington National Bank now owns 229 shares of the company’s stock worth $31,000 after buying an additional 97 shares during the period. Geneos Wealth Management Inc. lifted its stake in shares of Neurocrine Biosciences by 143.6% during the first quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock worth $25,000 after buying an additional 135 shares during the period. GeoWealth Management LLC lifted its stake in shares of Neurocrine Biosciences by 65.4% during the fourth quarter. GeoWealth Management LLC now owns 258 shares of the company’s stock worth $35,000 after buying an additional 102 shares during the period. WPG Advisers LLC acquired a new stake in shares of Neurocrine Biosciences during the first quarter worth $32,000. Finally, Smallwood Wealth Investment Management LLC acquired a new stake in shares of Neurocrine Biosciences during the first quarter worth $34,000. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.